Universidad de Castilla-La Mancha, Regional Centre for Biomedical Research, Spain; Universidad de Castilla-La Mancha, Biochemistry Section, Faculty of Science and Chemical Technologies, Avda Camilo José Cela 10, 13071 Ciudad Real, Spain.
Universidad de Castilla-La Mancha, Regional Centre for Biomedical Research, Spain; Universidad de Castilla-La Mancha, Biochemistry Section, Faculty of Environmental Sciences and Biochemistry, Avda. Carlos III s/n, 45071 Toledo, Spain.
Metabolism. 2021 Feb;115:154453. doi: 10.1016/j.metabol.2020.154453. Epub 2020 Nov 27.
Cardiovascular disease in obese individuals with type 2 diabetes is often associated with hyperleptinemia and leptin resistance, while other studies support that leptin has cardioprotective effects. Besides, the role of leptin in regulating cardiac atrophy or hypertrophy remains to be clearly defined. In fact, in rats with normal leptin sensitivity, the molecular underpinnings of the effects of central leptin regulating cardiac structural pathways remain poorly understood.
Hence, we assessed the effects of intracerebroventricular (icv) leptin infusion on cardiac remodeling analyzing FOXO1/3 and mTORC1 pathways, focusing special attention to PPARβ/δ as mediator of central leptin's effects on cardiac metabolism.
Male 3-months-old Wistar rats, infused with icv leptin (0.2 μg/day) for 7 days, were daily co-treated intraperitoneally with the specific PPARβ/δ antagonist GSK0660, at 1 mg/kg per day along leptin treatment.
Central leptin regulated dynamically, in an opposite manner, the network between FOXOs and mTORC1 and induced an atrophy-related gene program in cardiac tissue. Leptin activated the anti-hypertrophic kinase GSK3β and increased the protein levels of muscle-specific ubiquitin ligases, muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx)/Atrogin-1 involved in limiting cardiac hypertrophy. FOXO1 activity and the expression of their target genes, Sod2 and Lpl, were also increased in the heart upon central leptin infusion. Besides, Beclin-1 and LC3B-II, gene products of the autophagic pathway response, were upregulated, while the content and expression levels of phenotypic markers of cardiac hypertrophy as ANP and β-myosin heavy chain, gene product of Myh7 were significantly decreased. On the other hand, mTORC1 activity and OXPHOS protein levels were decreased suggesting a key role of central leptin preventing cardiac oxidative stress. In fact, the content of carbonylated proteins, TBARS and ROS/RSN were not increased in cardiac tissue in response to central leptin infusion. Finally, the pharmacological inhibition of PPARβ/δ, via in vivo administration of the selective antagonist GSK0660, blunted the induction of FOXO1/3, Atrogin-1, MuRF1 and GSK3β in the heart mediated by icv leptin infusion.
Our results demonstrate that, in lean rats with normal leptin sensitivity, central leptin regulates nutrient sensing pathways in heart contributing to balance cardiac remodeling through the anti- and pro-hypertrophic programs, and in this process is involved PPARβ/δ.
肥胖 2 型糖尿病患者的心血管疾病通常与高瘦素血症和瘦素抵抗有关,而其他研究则支持瘦素有心脏保护作用。此外,瘦素在调节心脏萎缩或肥大中的作用仍有待明确界定。事实上,在瘦素敏感性正常的大鼠中,中枢性瘦素调节心脏结构途径的分子基础仍知之甚少。
因此,我们评估了脑室内(icv)瘦素输注对心脏重构的影响,分析了 FOXO1/3 和 mTORC1 途径,特别关注 PPARβ/δ 作为中枢性瘦素对心脏代谢影响的介导物。
雄性 3 个月大的 Wistar 大鼠,每天脑室内输注(icv)瘦素(0.2μg/天)7 天,每天腹膜内同时给予特异性 PPARβ/δ 拮抗剂 GSK0660,每天 1mg/kg 与瘦素一起治疗。
中枢性瘦素以相反的方式动态调节 FOXO 和 mTORC1 之间的网络,并在心脏组织中诱导一种与萎缩相关的基因程序。瘦素激活了抗肥大激酶 GSK3β,并增加了肌肉特异性泛素连接酶肌肉 RING 指 1(MuRF1)和肌肉萎缩 F 盒(MAFbx)/Atrogin-1 的蛋白水平,这些酶参与限制心脏肥大。FOXO1 活性及其靶基因 Sod2 和 Lpl 的表达也在中枢性瘦素输注后增加。此外,自噬途径反应的基因产物 Beclin-1 和 LC3B-II 上调,而心脏肥大的表型标志物 ANP 和β-肌球蛋白重链(Myh7 的基因产物)的含量和表达水平显著降低。另一方面,mTORC1 活性和 OXPHOS 蛋白水平降低表明中枢性瘦素防止心脏氧化应激的关键作用。事实上,心脏组织中羰基蛋白、TBARS 和 ROS/RSN 的含量并没有因中枢性瘦素输注而增加。最后,通过体内给予选择性拮抗剂 GSK0660,抑制 PPARβ/δ 的药理学抑制作用,减弱了中枢性瘦素输注诱导的心脏中 FOXO1/3、Atrogin-1、MuRF1 和 GSK3β 的诱导。
我们的结果表明,在瘦素敏感性正常的瘦大鼠中,中枢性瘦素调节心脏中的营养感应途径,通过抗和促肥大程序有助于平衡心脏重构,在此过程中涉及 PPARβ/δ。